3.3 Related Research
3.3.6 Data Mining
Cancer antigens (CA 15-3 and CA 27.29) showed some clinical utility and may be used for diagnosis and prognosis in women with breast cancer.
Circulating immune complexes measurement has no diagnostic utility for breast cancer in women from the studied racial/ethnic group; however once the baseline value has been established may be used to monitor treatment progression and recurrences.
The pro-inflammatory cytokines (IL-1 and TNF-α) and serum immunoglobulins (IgG, IgM and IgA) do not vary significantly in breast disease conditions.
Published work:
Chukurah E. F, Emele, F. E, Iyare F. E, Nwigwe C. G, Ogbodo S. O (2016). Evaluation of circulating immune complexes in patients with malignant and pre-malignant disease conditions of the breast in South-Eastern Nigeria. Journal of disease and Global Health, 5(4):211-217 (Appendix xxiii)
Chukwurah E. F, & Emele F. E (2006). Evaluation of serum cancer antigens (CA 15-3 and CA 27.29) and circulating immune complexes as important tools in the management of breast cancer in Nigeria. International Congress of Immunolgy: Accepted Conference paper abstract (Appendix xxiv).
REFERENCES
Ababa M. M, Balogun M. O, Kolawole C. A, Dragundale F. A, Adebayo R. F (2012).
Relationship between C-reactive protein and body mass index in Nigerians with type II diabetes mellitus. Nigerian Journal Clinical Medicine, 4 (3):46-51.
Abbasis A, Othman F, Einollahi N, Dashti N, Nabatchran F, and Ismail P. (2009). Risk factors for breast cancer in Iranian women: a case-control study. International Journal of Cancer Research, 5(1):1-11.
Abdalla I, Thisted R. A, Heimann R. (2000). The impact of contalateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer Journal, 6(4): 266-272.
Abdelnoor A. M, Kobeissy F, Farhat D, Hadi U. (2002). Some Circulating immunological aspects of patients with rhinitis in Lebanon. Immunopharmacology and Immunotoxicology, 24(2): 289-301.
Abdelnoor A. M, Kobeissy F, Farhat D, Hadi U. (2004). Circulating immune complexes and complement C3 and C4 levels in selected group of patients with, rhinitis in Lebanon. Clinical and Molecular Allergy, 2: 6-8.
Adam J. K, Odhav B, Bhoola K. D. (2003). Immune response in cancer. Pharmacology and Therapeutics, 99(1): 113-132.
Adebamowo C. A, Adekunle O. O. (1999). Case-control study of the epidemiological risk factors for breast cancer in Nigeria. British Journal of Surgery, 86(5): 665-668.
Adebamowo C, Ogundiran T. O, Adenipekun A. A, Oyesegun R. A, Campbell O. B, Akang E. E, Rotimi C. N, and Olopade O. I (2003). Waist-hip-ratio and breast cancer in urbanized Nigerian women. Breast Cancer Research, 5(2):18-24.
Adebamawo C. A, Ogundiran T O, Adenipekun A. A, Oyesegun R. A, Campbell O. B, Akang E. U, Rotimi C. N, Olapade O I. (2003). Obesity and Height in Urban Nigerian Women with Breast Cancer. Annals of Epidemiology, 13 (6): 455-461.
Adeniji K. A. (1999). Pathological appraisal of carcinoma of the female breast in Ilorin Nigeria. Nigerian Postgraduate Medical Journal, 6(2):56-59.
Adetifa F. A. and Ojikutu, R. K (2009) Prevalence and Trends in Breast Cancer in Lagos State, Nigeria. An International Multi-Disciplinary Journal, Ethiopia, 3(5): 1-15.
Adisa C. A, Eleweke N, Alfred A. U, Cambell M. J, Sharma R, Nseyo O, Tandon V, Mukhfar R, Greninger A, Di Risi J, Esserman L. J. (2012). Biology of breast cancer in Nigerian women: A pilot Study. Annals of African Medicine, 11 (3): 169-175.
Afonso N. (2009). Women at high risk for breast cancer- what the primary care provider needs to know. The Journal of the American Board of Family Medicine, 22(1):43-50.
Aggarwal B. B, Shishodia S, Sandur S K, Pandey M. K, Sethi G (2006 Inflammation and cancer: How hot is the link? Biochemical Pharmacology, 72(11): 1605-1621.
Ahmed H. U, Zacharakis E, Dudderidge T, Armitage J. N, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M. (2009). High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.
British Journal of Cancer, 101(1):19-26.
Akarolo-Anthony S. N, Ogundiran T. O, and Adebamowo C. A. (2010). Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Research, 12(4):8.
Akpa M. R, Mato C. N (2008). Obesity in Nigeria: Current trends and management.
Nigerian Medical Practitioner, 54:11-15.
Alberts B, Bray D., Lewis J., Raff M., Roberts K., Watson J. D (1994). Molecular Biology of the Cell. Garland Publishing Inc. New York, London. 3rd Edition. pp 721-785.
Alberti K. G, Zimmet P, Shaw J. (2006). Metabolic syndrome. Diabetic Medicine, 23(5):
469-480.
Albert M. A (2007). Inflammatory biomarkers, race/ethnicity and cardiovascular disease.
Nutrition Reviews, 65:S234–S238.
Alberti K. G. M. M, Eckel R. H, Grundy S. M, Zimmet P. Z, Cleeman J. I, Donato K.. A, Fruchart J, James W.P.J, Loria C. M, Smith S. C, (2009). Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
Circulation, 109:1926 -1944.
Albonico H. U. Braker H. U, Husler J. (1998) Febrile infectious childhood diseases in the history of cancer patients and matched controls. Medical Hypotheses, 51: 315-320.
Alderton G. K and Bordon Y. (2012). Tumour immunotherapy – Leucocytes take up the fight. Nature Reviews – Immunology, 12: 237-239.
Al-Hassan A, Muhymen N. A, Hussien A. G, Mustafa L. K, Al-Obeidy E. S (2010).
Possible Role of IL-1-α and TNF-α in Breast Cancer. Iraqi Journal of Medical Science, 8 (1): 11-17.
Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar S. S. (2011). Notch Signaling Pathway as a Therapeutic Target in Breast Cancer. Molecular Cancer Therapeutics, 10(1): 9-15.
Allenspach E. J., Maillard I., Aster J. C., Pear W. S. (2002). Notch signaling in cancer.
Cancer Biology and Therapy, 1:5, 466-476.
American Academy of Family Physicians (2003). Serum tumour markers. American Academy of Family Physician, 68: 1075-1082.
American Cancer Society. (2007). Detailed guide: Breast Cancer: What are the risk factors
for breast cancer. [Online]. Available from:
http://www.cancer.org/docroot/CRI/content_2_4_2X. [Accessed September 5th, 2013].
American Heart Association. (2014). The CVD Epidemiology: Socioeconomic Status, Race and Other Risk Factors Abstract 12141: Temporal Trends in the Characteristics of Autopsy-Verified Victims of Sudden Cardiac Death Without a Known Prior Cardiac Disease. American Heart Association, A12141.
American Heart Association (2014). Body mass index in adults. (BMI calculator for adults) {Accessed online, Feb 2015}.
American Institute for Cancer Research (2007). Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. American Institute for Cancer Report (AICR Blog), 11: 36-39.
American Institute for Cancer Research.( 2007). Guidelines for cancer-prevention: healthy living for cancer prevention. [Online]. Available from: http://www.aicr.org.
[Accessed August 6th, 2014].
American Institute for Cancer Research (2008). American Institute for Cancer Research (2007). Food Guidance for Tots. American Institute for Cancer Report (AICR Blog).
Ansa V. O, Odigwe C. O, Anah M. U (2001). Profile of body mass index and obesity in Nigerian children and adolescents. Nigerian Journal Medicine, 10:78-80.
Antoma S.J; Mirza N, Frieke J. (2006) Combination of p53 cancer vaccine with chenmotherapy in patients with extensive stage small cell lung cancer. Clinical Cancer Research, 12: 878-887.
Anyanwu S. N. (2000). Breast cancer in eastern Nigeria: A ten year review. West African Journal of Medicine, 19: 120-125.
Apostolopoulos V, Pietersz G. A, Tsibanis A, Tsikkinis A, Drakaki H, Loveland B. E, Piddlesden S. J, Plebanski M, Pouniotis D. S, Alexis M. N, McKenzie I. F, Vassilaros S. (2006). Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Research, 8:R27 doi:10.1186/bcr1505.
Armstrong K. A, and Weber B. (2000). Assessing the risk of breast cancer. The New England Journal of Medicine, 342: 564-571.
Ascierto, P. A., Kirkwood, J. M., Grob, J. J., Simeone, E., Grimaldi, A. M., Maio, M., Palmieri, G., Testori, A., Marincola, F. M., Mozzillo, N. (2012). The role of BRAF V600 mutation in melanoma, Journal of Translational Medicine, 10:85
Assi H. A, Khoury K. E, Dbouk H, Khalil L. E, Mouhieddine T. H, Saghir N. S (2013).Epidemiology and prognosis of breast cancer in young women. Journal of Thoracic Diseases, 15 (1): doi: 10.3978/j.issn.2072-1439, (online).
Atoyebi O. A, Atimomo C. E, Adesanya A. A, Beredugo B. K, da Rocha-Afodu J. T.
(1997). An appraisal of 100 patients with breast cancer seen at Lagos University Teaching Hospital. Nigerian Quarterly Journal of Hospital Medicine, 7:104-108.
Ayoade B. A, Tade A. O, Salami B. A (2012).Clinical Features and Pattern of Presentation of Breast Diseases in Surgical Outpatient Clinic of a Suburban Tertiary Hospital in South-West Nigeria. Nigerian Journal of Surgery, 18(1): 13–16.
Ayyoub, M. S. Stevanovic, U. Sahin, P. Guillaume, C. Servis, D. Rimoldi, D. Valmori, P.
Romero, J. C. Cerottini, H. G. Rammensee, M. Pfreundschuh, D. Speiser, and Levy F (2002). Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. Journal of Immunology, 168: 1717-1722.
Balkwill F. (2002). Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Review, 13: 135-141.
Balkwill F., Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357:539-545.
Banerji S, Cibulskis K, Rangel-Escareno K, Brown K. K, Carter S. L, Frederick A M.
(2012). Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 486: 405-409.
Bargmann C. I, Hung M. C, Weinberg R. A. (1986). The neuoncogene encodes an epidermal growth factor receptor related protein. Nature, 319: 226-230.
Barksby H. E, Lea S. R, Preshaw P. M, Taylor J. J (2007). The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clinical Experimental Immunology, 149(2): 217–225.
Basuyan J. P, Blanc-Vincent M. P, Bidarf J. M, Daver A, Deneux L, Eche N, Gory-Delabaere G, Pichon M. F, Riedinger J. M. (2000). Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group.
Bulletin of Cancer, 87(10): 723-737.
Bates S. E (1991). Clinical applications of serum tumor markers. Annals of Internal Medicine, 115: 623-638.
Beeker K. G, Barnes K. C, Bright T. J, Wang S. A. (2004). The Genetic Association Database. Nature Genetics, 36: 431 – 432.
Begum P, Richardson C. E, Carmichael A. R. (2009). Obesity in post-menopausal women with a family history of breast cancer: prevalence and risk awareness. International Seminars in Surgical Oncology, 6(1):1-5.
Belous A. R, Hachey D. L, Dawling S, Roodi N, Parl F. F. (2007). Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Research, 67(2): 812-817.
Benacerraf B, Katz D. H; (1975) The Histo-compatibility linked immune response genes.
Advances in Cancer Research, 21:121-175.
Ben-Baruch A. (2003). Review: Host microenviroment in breast cancer development.
Inflammatory cells cytokines, chemokines in breast cancer progression: Reciprocal tumour microenviroment interactions. Breast Cancer Research, 5: 31-36.
Bentley J. R, Delfino R. J, Taylor T. H, Howe S, Anton-Culver H. (1998). Difference in breast cancer stages at diagnosis between non-Hispanic white and Hispanic populations, San Diego County 1988-1993. Breast Cancer Research and Treatment, 50:1-9.
Berberoglu U, Yildirim E, Celen O (2004). Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. International Journal of Biological Markers, 19(2):130-134.
Berkow R and Beers M. H (1997). Cancer and Immune system. In the Merck Manual of Medical Information. Whitehouse Station, NJ, Mercks Research Laboratories, pp 792-794.
Bernstein H, Payne C. M, Bernstein C, Garewal H, Dvorak K (2008). Cancer and aging as consequences of un-repaired DNA damage. In: New Research on DNA Damages (Editors: Honoka Kimura and Aoi Suzuki) Nova Science Publishers, Inc., New York, Chapter 1, pp. 1-47.
Berruti A, Tampellium M, Torta M, Buniva T, Gorzegno G, Dogliotti L. (1994) Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. European Journal of Cancer, 30A: 2082-2084.
Berstad P, Coates R. J, Bernstein L, Suzanne G. Folger S. G, Malone, K. E, Marchbanks P.
A, Weiss L. K, Liff J. M, McDonald J. A, Strom B. L, Simon M. S, Deapen D, Press M. F, Burkman R. T, Spirtas R, Ursin G. (2010). A Case-Control Study of Body Mass Index and Breast Cancer Risk in White and African-American Women.
Cancer Epidemiology, Biomarkers and Prevention, 19: 1532-1544.
Bhatt A N, Mathur R, Farooque A, Amit Verma A, B.S. Dwarakanath B. S (2010). Cancer biomarkers - Current perspectives. Indian Journal of Medical Research, 132: 129-149.
Bingham S. (2000). Diet and cancer prevention, In Human nutrition and dietetics.Ed. by Garrow J.S, James W.P.I, and Ralph A. 10th Ed. New York: Churchill Livingston.
Pp 764-774.
Blume-Jensen P and Hunter T. (2001). Oncogenic kinase signaling. Nature, 411: 355-365.
Bonney R. J, Wightman P. D, Davies P, Humes J. L. (1979). Immune complexes cause the synthesis and release of lysosomal acd hydrolysis from macrophages. European Journal of Rheumatology and Inflammation, 2: 230-235.
Borrell L. N, Castor D, Conway F. P, Terry M. B. (2006). Influence of nativity status on breast-cancer risk among US black women. Journal of Urban Health, 83(2):211-220.
Bosman J. P, Kritzinger J. P. K, Meiring J. H, Schumann C. J, Abrahams P. H, and Greyling L. M. (2008). Medical terminology for students of the health professions. Cape Town: Paarl Printing, pp 149-171.
Boyer J. and Liu R. H. (2004). Apple phytochemicals and their health benefits. Nutrition Journal, 3(5):1186-2891.
Bradley J. R. (2008). TNF-mediated inflammatory disease. Journal of Pathology, 214(2):
149-160.
Brawley O. W. (2002). Some perspective on black-white cancer statistics. A Cancer Journal for Clinicians, 52(6):322-25.
Briasoulis E, Andreopoulou E, Tolis C. F, Bairaktari E, Katsaraki A, Dimopoulos M. A, Fountzilas G, Seferiadis C, Pavlidis N (2001). G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting.
Cancer, 91(5): 909-917.
Brickkell P. M, Lanchman D S, Murphy D, William K and Rigby P W J (1983).Implication of MHC in antigen presentation in tumor. Nature, 386: 756-760.
Buckhaults P, Chen L, Fregien N, Pierce M. (1997). Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. Journal of Biochemical Chemistry, 272:19575-19581.
Bukh A, Aguado M. T, Krarup N, Poulsen H. S, Nordentoft A. M, Møller N. P (1988). A prospective study of circulating immune complexes in patients with breast cancer.
International Journal of Cancer, 41(3):364-370.
Caestecker M. P, Piek E, Roberts A. B.(2000). Role of Transforming Growth Factor-β Signaling in Cancer. Journal of National Cancer Institute, 92 (17): 1388-1402.
Calle E. E, Rodriquez C, Walker-Thurmond K, and Thun M. J. (2003). Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. Adults. The New England Journal of Medicine, 348:1625-1638.
Cano R, Isenberg J. I, Crossman M. I. (1976). Cimetidine inhibits caffeine-stimulated gastric secretion in man. Gastroenterology, 70: 1055-1057.
Carini C and Brostoff J. (1987). Evidence of circulating IgE complexes in food allergy.
Ricerca in clinica e in laboratorio, 17(4): 253-259.
Castellano E., Sheridan C., Thin M. Z., Nye E., Spencer-Dene B., Diefenbacher M. E., Moore C., Kumar M. S., Murillo M. M., Grönroos E., Lassailly F., Stamp G., Downward J. (2013). Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance. Cancer Cell, 24(5): 617–630.
Cavallo F, Offringa R, Vander Burg S H, Forni G, Melief C (2006) Vaccination for treatment and prevention of cancer in animal models. Advances in Immunology, 90:
175-273.
Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. (2010). Tumour associated carbohydrate antigens in breast cancer. Breast Cancer Research, 12: 204-214.
Celik S and Aksoy G. (2007). Identification of risk factors for breast cancer for women in Istanbul. The Open Nursing Journal, 1:6-12.
Cen P, Duvic M, Cohen P.R, Kurzrock R (2008).Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. Journal of American Academy of Dermatology, 58(3): 382-386.
Centre for Disease Control (CDC), (2014). The United States Cancer Statistics: 1999–2012 Incidence and Mortality Web-based Report. Centre for Disease control.
Centre for Disease Control (CDC), (2014). Healthy weight – it‘s not a diet its lifestyle.
(Accessed online; February 2015).
Challis G. B, Stam H. J. (1990).The Spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncologica, 29: 545-550.
Chaloob F. A (2014). Estimation of serum levels of GM-CSF, IL-1 and Complement Components C3 and C4 in Patients with Chronic HCV. International Journal of Current Microbiology and Applied Sciences, 3(3): 695-699.
Chang F., Lee J. T., Navolanic P. M., Steelman L. S., Shelton J. G., Blalock W. L., Franklin R. A., McCubrey J. A. (2003). Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. .Leukemia, 17: 590–603.
Chang S. C, Ziegler R. G, Dunn B, Stolzenberg-Solomon R, Lacey J. V, Huang W. Y Jr., Schatzkin A, Reding D, Hoover R. N, Hartage P, and Leitzmann M. F. (2006).
Association of energy intake and energy balance with postmenopausal breast cancer in prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiology Biomarkers and Prevention, 15:334-341.
Chaudhuri D. R., Suriano A. M., Tiwari R. K (2009). Targeting the immune system in cancer. Current Pharmacology & Biotechnology, 10:166-184.
Chen C., Boxer R. B., Stairs D. B., Portocarrero C. P., Horton R. H., Alvargz J. V., Birnbaum M. J., Chodash L. A. (2010). AKT is required for Stat5 activation and mammary differentiation. Breast Cancer Research, 12: R72.
Chen Y, Thompson W, Semenciw R, Mao Y. (1999). Epidemiology of contralateral breast cancer. Cancer Epidemiology, Biomarkers and Prevention, 8(10):855-861.
Chen Y, Thomson W, Semenciw R, Mao Y. (1999). Epidemiology of contralateral breast cancer. Cancer Epidemiology, Biomarkers and Prevention, 8 (10): 855-861.
Chen Y. T, Scanlan M. J, Obata Y, Old L. J (2000). Identification of human tumor antigens by serological expression cloning. In Principles and Practice of Biologic Therapy of Cancer.Edited by Rosenberg S. A. Philadelphia PA: Lippincott Williams and Wilkins, 557-570.
Chiedozi L. C. (1989). Breast cancer in Nigeria. Cancer, 55(3): 653-657.
Chikamatsu K, Nakano K, Storkus W. J, Appella E, Lotze M. T, Whiteside T. L, DeLeo A.
B. (1999). Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clinical Cancer Research, 5:1281-1288.
Chinedu S. N, Ahmed H, Airede K (2013). Body mass index among school adolescents in Sokoto, North-Western Nigeria. Sahel Medical Journal, 16:5-9.
Clemons M and Goss P. (2001). Estrogen and the risk of breast cancer. The New England Journal of Medicine, 344(4):276-285.
Colomer R, Ruibal A Genoll J and Salvador L (1989). CA 15-3 levels in non mammary malignancies. British Journal of Cancer, 59 (2): 283-286.
Crose M. V and Segal-Eiras A (1996). Identification of acute phase protein and CIC in esophageal cancer patient‘s sera. Cancer Investigations, 14 (5): 421-426.
Crowther M, Brown N. J, Bishop E. T, Lewis C. E (2001). Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. Journal of Leukocyte Biology, 70:478-490.
D‘Souza D. Jean J, Jaykus L. (2004). Multiplex NASBA for the detection of hepatitis A and Norwalk viruses in foods. Applied and Environmental Microbiology, 70: 6603-6610.
Dass T. K, Aziz M, Rattan A, Tyagi S. P (1992) Clinical utility and monitoring of breast cancer by circulating immune complexes. Indian Journal of Pathology &
Microbiology, 35(4):298-307.
De Caestecker M. P., Piek E., Roberts A. B. (2000). Role of transforming growth factor-beta signaling in cancer. Journal of National Cancer Institute, 92(17): 1388-1402.
De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. (1999). DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Molecular and Cellular Biology, 19:7327-7335.
De Smet, C., Lurquin C, van der B. P, De P. E, Brasseur F, and Boon T. (1994). Sequence and expression pattern of the human MAGE2 gene. Immunogenetics, 39: 121-129.
de Visser K. E, Eiethen A, Coussen L. M (2006). Paradoxical roles of immune system during cancer development. National Review of Cancer, 6: 24-37.
Decker T, and Kovarik P. (1999). Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cellular
& Molecular Life Sciences, 55:1535-1546.
DeNardo D. G, Brennan D. J, Rexhepaj E (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1 (1): 54-67.
Denkert C, Loibl S, Noske A (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology, 28 (1): 105-113.
Di Lorenzo G, Buonerba C, Kantoff P. W (2011). "Immunotherapy for the treatment of prostate cancer". Nature Reviews: Clinical Oncology, 8 (9): 551–561.
Dickson B. C., Mulligan A. M., Zhang H. (2007). High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Modern Pathology, 20:685–693.
Dimitrakakis C, Jones R. A, Liu A, and Bondy C. A. (2004).Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy.
The Journal of the North American Menopause Society, 11(5):531-535.
Dinarello C. A. (1997). Interleukin-1. Cytokine Growth Factor Review, 8(4): 253-265.
Dinarello C. A. (2009). Immunological and inflammatory functions of the interleukin-1 family. Annual Review of Immunology, 27:519-550.
Disi M. L and Park K. H (2009).Immunomodulation of breast cancer via tumour antigen specific Th1. Cancer Research and Treatment, 41(3):117-121.
Disis M. L, Grabstein K. H, Sleath P. R, Cheever M. A. (1999). Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clinical Cancer Research, 5:1289-1297.
Djordjevic S, Driscoll P C (2002). Structural insight into substrate specificity and regulatory mechanisms of phosphoinositide 3-kinases. Trends in Biochemical Science, 27:
426–432.
Dossus L and Kaaks R. (2008). Nutrition, metabolic factors and cancer risk. Best practice and research clinical endocrinology and metabolism, 22(4):551-571.
Drabsch Y., He S., Zhang L., Snaar-Jagalska B. E., Dijke P. T. (2013). Transforming growth factor-β signaling controls human breast cancer metastasis in a zebrafish xenograft model. Breast Cancer Research, 15: R106.
Duffy M. J, Shering S, Sherry F, McDermott E, O'Higgins N (1999). CA 15-3: a prognostic marker in breast cancer. International Journal of Biological Markers, 15(4): 330–
333.
Duffy, M. J.; Duggan, C.; Keane, R.; Hill A. D. K.; McDermott, E. Crown, J.; Higgins, N.
O. (2004). High pre-operative CA 15-3 concentrations predict adverse out come in node-negative and node-positive breast cancer. Study of 60 patients with histologically confirmed breast cancer. Clinical Chemistry, 50(3): 559-563.
Duffy, M.J. (2000). Serum tumour markers in breast cancer: Are they of clinical value.
Clinical Chemistry, 52: 345-351.
Dunn G. F, Old L J, Schreiber R.D (2004). The three Es of cancer immune editing. Annual Review of Immunology, 22: 329-360.
Dunn G. P, Brunce A. T, Ikeda H, Old L J, Schreiber R.D. (2002). Cancer immunoediting:
from immunesurveillance to tumor escape. Nature Immunology, 3(11): 991-998.
Duraker N, Hol S, Polat Y. (2007). CA 19-9 and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice Journal. Surgical Oncology, 95: 142-147.
Easton D. F. (2005). Study shows women of African ancestry diagnosed with more virulent form of breast cancer. The University of Chicgo Chronicle. 24 (15): 1-3.
Ebeling F. G, Stieber P, M. Untch M (2002). Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. British Journal of Cancer, 86(8): 1217–1222.
Ebrahim M, Vahdaninia M, and Montazeri A. (2002). Risk factors for breast cancer in Iran:
a case-control study. Breast Cancer Research, 4:10-13.
Echehakir H, Bagot M, Dorothes G (2000). Cutaneous T-cell lymphoma reactive CD4+
cytotoxic T lymphocyte clones display a Th1 cytokines profile and use a fas-independent pathway for specific tumor cell lysis. Investigative Dermatology, 115:
74-80.
Edge S. B; Byral D. R. Compton C. C; Fritz A. G; Greene F. L; Trotti A. (2010) AJCC cancer staging manual; 7th ED. New York, Springer.49-56.
Egawa K. (2004). Immuno-cell therapy of cancer in Japan. Anticancer Research, 24 (5C):
3321–3326.
Eiseman A, Murr C, Fucks D Ledochski M (2009). ―Gliadin IgG antibodies and circulating immune complexes‖. Scandinavian Journal of Gastroenterology, 44(2): 168-171.
Ellis M. J., Ding L., Shen D., Luo J., Suman V. J., Wallis J. W.(2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486: 353-360.
Ellisen L. W., Bird J., West D. C., Soreng A. L., Reynolds T. C., Smith S D. (1991). TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 66: 649-661.
Englaro W, Bahadoran P, Bertolotto C, Busca R, Derijard B, Livolsi A, Peyron J. F, Ortonne J. P, Ballotti R. (1999). Tumor necrosis factor α-mediated inhibition of melanogenesis is dependent on nuclear factor κ B activation. Oncogene, 18(8):
1553-1559.
Erdemir G., Ozkan T. B., Ozgur T, Budak F., Kilic S. S., Onay H. (2015). Mannose-binding lectin gene polymorphism and chronic hepatitis B infection in children. The Saudi Journal of Gastroenterology, 21(2): 84-89.
Espinoza L. R, Gaylord S. W, Bocanegra T. S, Vassey F. B, Germai B. F (1982).
Circulating immune complexes in the seronegative spondyoarthropathies. Clinical Immunology and Immunopathology, 32 (5): 879-885
Evans A and Costello E (2012). The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Frontiers in Physiology, 3: 270.
Ezeome E. R, Emegoakor C. D, Chianakwana G. U, Anyanwu S. N. C.(2010). The pattern of male breast cancer in Nigeria: A 12 year review. Nigerian Medical Journal, 51:26-29.
Ferlay J, Shin H. R, Bray F, Forman D, Mathers C, Parkin D. M. (2010). Estimates of worldwide burden of cancer in 2008. International Journal of Cancer, 127(12):2893-2897.
Filho R. M, Carmo R. F, Catsman C, Souza C, Silva A, Moura P (2010). High frequency of variant alleles of the mannose-binding lectin 2 (MBL2) genes are associated with patients infected by hepatitis B virus. Viral Immunology, 23:449-453.
Finn O. J. (2008). Molecular origin of cancer: Cancer Immunology. New England Journal of Medicine, 358: 2704-2715.
Finn O.J (2005). Immune Response as a Biomarker for Cancer Determination and a lot more. New England Journal of Medicine, 353: 1288-1290.
Foukas L.C., Claret M., Pearce W., Okkenhaug K., Meek S., Peskett E., Sancho S., Smith A.J., Withers D.J., Vanhaesebroeck B (2006). Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature, 441:
366–370.
Fox S. I. (2006). Human physiology; 9th edition, New York: McGraw-Hill Companies, Inc.
117-129.
Franklin R. A and McCubrey J. A (2000). Kinases: positive and negative regulators of apoptosis. Leukemia, 14: 2019–2034.
Fregene A, and Newman L. A. (2005). Breast cancer in Sub-saharan Africa. How does it relate to breast cancer in African-American women. Cancer, 103 (8): 1540- 1550.
Friedenreich C. M. (2001). Review of anthropometric factors and breast cancer risk.
European Journal of Cancer Prevention, 10(1):15-32.
Friedman L. M (2005). Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proceedings of National Academy of Science, 102: 1915-1920.
Fry M. J. (2001). Phosphoinositide 3-kinase signaling in breast cancer: how big a role might it play? Breast Cancer Research, 3: 304–312.
Gammon M. D, Hibshoosh H, Terry M. B, Bose S, Schoenberg J. B, Brinton L. A, Bernstein J. L, Thompson W. D (1999). Oral contraceptive use and other risk factors in relation to HER-2/neu: Over expression in breast cancer among young women. Cancer Epidemiology, Biomarkers and Prevention, 8: 413-419.
Gang Y, Adchi I, Chikura H, Yamamato, H, Mizuguchi Y, Abe K. (1985). CA 15-3 is present as a novel tumour marker in sera of patients with breast cancer and other malignancies. Gan To Kagaku Ryoho, 12 (12): 239-286.
Gardner T. A, Elzey B. D, Hahn N. M. (2012). "Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer." Human vaccines and immunotherapeutics, 8(4): 534–539.
Gee M, Mahan L. K, and Escott-Stump S. (2008). Weight management, In Krause‘s food and nutrition therapy. Ed. by Mahan LK and Escott-Stump S. 12th ed. Philadelphia:
W.B. Saunders Company. 532-562.
Geraghty J. G, Coveney E. C, Sherry F, Ohiggins N. J, Duffy M. J. (1992). Ca-15-3 in patients with locoregional and metastatic breast-carcinoma. Cancer, 70: 2831.
Ghai V, Sharma K, Abbi K. K. S, Harvey H. A (2011).Clinical Utility of Monitoring Serial CA 27.29 in Patients with Different Stage of Breast Cancer. The Open Breast Cancer Journal, 3: 29-30.
Ghar R. F. (2001). Allergic Asthma: In case studies in Immunology. 3rd Edn; New York Garland Pub.127-134.
Gibson L. J, Héry C, Mitton N, Gines-Bautista A, Parkin D. M, Ngelangel C, and Pisani P.
(2010). Risk factors for breast cancer among Filipino women in Manila.
International Journal of Cancer, 126(2): 515-521.
Gogas J, Markopoulos C, Skandalakis P, Gogas H. (1993). Bilateral breast cancer.
American Surgery, 59(11):733-735.
Gold P, Freedman S.O (1965) Demonstrating TSA in human colonic carcinomata by immunogenic tolerance and absorption technique. Journal of Experimental Medicine, 121: 439-462.
Gong M. N, Zhou W, Williams P. L, Thompson B. T, Pothier L, Christiani D. C (2007). Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Critical Care Medicine, 35(1): 48–56.
González C. A, Sala N, Rokkas T (2013). "Gastric cancer: epidemiologic aspects".
Helicobacter, 18 (1): 34–38.
Grant B. (2008). Medical Nutrition Therapy for Cancer, In Krause‘s food and nutrition therapy. Ed. by Mahan, K.L. and Escott-Stump, S.12th ed. Philadelphia: Saunders:
959-990.
Greaves M. F (1981). Antigens of human leukaemic cells. Cancer Research, 41: 4752-4766.
Green A. R, Green V. L, White M. C, Speirs V (1997). Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. International Journal of Cancer, 72:
937-941.
Grigoriadis A, Caballero O. L , Hoek K. S, da Silva L, Chen Y, Tungbluth A. A, Miller L.
D, Cloustone D, Old L, Lakhani S. R, Simpson A. J. G, Neville A. (2009). CT-X antigen expression in human breast cancer. Proceedings of the National Academy of Sciences, 106(32): 13493-13498.
Grivennikov S. I and Kari M (2011). Inflammatory cytokines in cancer: TNF and IL-6 take the stage. Annals of Rheumatic Diseases, 1: 1104-1108.
Grzywa R, Łupicka-Słowik A, Walczak M, Idzi M, Bobrek K, Boivin S, Gawel A, Stefaniak T, Oleksyszyn J, Sienczyk M (2014). Highly sensitive detection of cancer antigen 15-3 using novel avian IgY antibodies. ALTEX - ncbi.nlm.nih.gov (online:
accessed February 2015).
Guille A., Chaffanet M., Birnbaum D. (2013). Signaling pathway switch in breast cancer.
Cancer Cell International, 13(1): 66.
Gupta R. A (1995). A New Immunologic Method for Detection of Occult Breast Cancer.
Cancer Research, 39:1683-1695.
Guyton A. C, Hail J E eds. (1997) Immunity, Allergy, blood groups and transfusion. In Human Physiology and mechanisms of disease 6th Ed. Philadelphia, P A: W. B Saunders company; 291-293.
Guyton A.C, Hail J. E (2000). Resistance of the body to infection; II.Immunity and allergy.
In textbook of medical physiology 10th ed. Philadelphia P. A: W B Saunders Company 409-410.
Halilovic E., She Q. B., Ye Q., Pagliarini R., Sellers W. R., Solit D. B., Rosen N (2010).
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Research, 70: 6804–6814.
Hammond A (2008). Assessment: Dietary and clinical data, In Krause‘s food and nutrition therapy. Ed. by Mahan, K.L. and Escott-Stump, S.12th ed. Philadelphia: Saunders:
383-402.
Hanaham D, Coussens L. M (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell, 21:309–322
Handa O, Naito Y, Yoshikawa T. (2011). Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Report, 16(1):1-7.
Hareuveni M, Gautier C, Kieny M, Wreschner D, Chambon P, Lathe R (1990). Vaccination against tumour cells expressing breast cancer epithelial tissue antigen. Proceedings of National Academy of Science, 87: 9498-9505.
Hattrup C. L, and S. J. Gendler S. J (2008). Structure and function of the cell surface (tethered) mucins. Annual Review of Physiology, 70: 431–457.
Haughton G, Whitemore A.C (1976) Genetics, the Immune response and oncogenesis.
Transplantation Reviews, 28:75-97.
Hausen H (2000). Pappilloma viruses causing cancer: Evasion for Host-cell control in Early Events in Carcinogenesis. Journal of National Cancer Institute, 92(9): 690-698.
Hay N, Sonenberg N (2004). "Upstream and downstream of mTOR" Genes Development, 18 (16): 1926–1945.
Hayes D. F and Schnitt S. J. (1993).Risk factors, Epidemiology, and Development of Breast Cancer, In Atlas of Breast Cancer. Ed. by Hayes, D.F. Hong Kong: Everbest Printing Company, Inc: 2.2.
Heaney M (1985). Immune complexes and disease: In introduction to clinical immunology 3rd edn. Butterworths London 48-52.
Heavey P. M and Rowland I. R (1999). The gut microflora of the developing infant:
microbiology and metabolism. Microbial Ecology in Health and Disease, 11:75-83.
Hebert L. A, Cosio F. G. (1987). The erythrocyte-immune complex-glomerulonephritis:
Connection in man. Kidney International, 31: 877-885.
Hendenfalk I, Duggan D, Chen Y, Radmacher M, Bitter M, Simon R, Meltzer P, Gutsterson B, Esteller M, Raffeld M, Zakhini Z, Ben-Dor A, Dougherty E, Kononen J, Bubendorf L, Fehrie W, Pittaluga S, Gruvberger S, Loman N, Johannsson O, Olsson H, Wilfond B, Sauter G, Kallionjemi O. P, Borg A, and Trent J. (2001). Gene-expression profiles in hereditary breast cancer. The New England Journal of Medicine, 344:539-548.
Herpin A., Lelong C., Favrel P. (2004). Transforming growth factor-beta-related proteins:
an ancestral and widespread superfamily of cytokines in metazoans. Development and Comparative Immunology, 28 (5): 461–485.
Hodge J. W. (1996). Carcino-embryonic antigen as a target for cancer vaccines. Cancer Immunology & Immunotherapy, 43:127-134.
Hoffken I. C, Merdith I. D, Robins R. F, Baldwin R. W, Davies C. J, Balmey R. W (1977).Circulating immune complexes in patients with breast cancer. British Medical Journal, 2: 218-220.
Hoffman S. C, Stanley E. M, Cox E. D, DiMercurio B. S, Koziol D. E, Harlan D. M (2002).
Ethnicity greatly influences cytokine gene polymorphism distribution. American Journal of Transplantation, 2:560–567.
Hofken, I. C.; Merdit, I. D.; Robins, R. F.; Baldwin, R. W.; Davies, C. J.; Balmey, R. W.
(1977). Circulating immune complexes in patients with breast cancer. British Medical Journal, 2: 218-220.
Hohlfeld P, Dang T. T, Nahoul K, Daffos F, Forestier F. (1994).Tumour-associated antigens in maternal and fetal blood. Prenatal Diagnosis, 14: 907-912.
Houssami N and Ciatto S. (2010).Mammographic surveillance in women with a personal history of breast cancer. The Breast, 19(6):439-445.
Houston A, Benett M W, O‘Sullivan G.C Shanala F, O‘Councell J (2003) Fas Logand Mediates Immune privilege and not inflammation in human colon Cancer, irrespective of TGF-β expression. British Journal of Cancer, 89:1345-1351.
Hunter K. W and Crawford N. P. (2006).Germ line polymorphism in metastatic progression.
Cancer Research, 66(3):1251-1252.
Hussain S. K, Altieri A, Sundquist J and Hemminki K (2008). Influence of education level on breast cancer risk and survival in Swedish between 1990 and 2004. International Journal of Cancer, 122(1): 165-169.
Hwang G; Lin C; Huang L; Wang Y; Wang J; Hsu C; Yang S; Wu C (2003). Detection of Hepatitis B virus x protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. Journal of Clinical Microbiology. 4 (12) : 5598 - 5603.
Hynes. N. and MacDonald G. (2009): ErbB receptors and signaling pathways in cancer.
Current Opinions in Cell Biology, 21:177-184.
Ihekwaba F. N (1992). Breast cancer in Nigerian women. British Journal of Cancer, 79 (8):
771-775.
Inganas Johansson S. G. O, Dannaeus A. (1979). A method for estimation of circulating immune complexes after oral challenge with ovalbumin.DOI 10.IIII/j.1365-2222.1980.tb110.x.
Inman R. D; Rosenberg R. A; Redecha P. B; Christian C. L (1984). Characterization of sequential immune complexes in infectious endocarditis by Western blot analysis.
Journal of Immunology. 133 (1) : 217 - 221.
Innade Y, Kamiyam M, Kanemitsu T, Clark W. S. (1981). ―A new application of immune adherence haemaglutination‖. Annales de l’Insttute.Pasteur: Immunologica, 132(2);
181-190.
Innes K, Byers T, and Schymura M (2000). Birth characteristics and subsequent risk for breast cancer in young women. American Journal of Epidemiology, 152(12):1121-1128.
Ipp T; Macnab G. M; Geddes E. W; Keo M. C; (1975). Serum immunoglobulin levels in primary liver cancer: relationship to underlying cirrhosis and hepatitis-B (surface antigenemia). British Journal of Cancer, 32 (4): 509-511.
Irvin W. J Jnr. and Carey L. A. (2008). What is triple-negative breast cancer? European Journal of Cancer, 44(18):2799-2805.
Ishq M., Rani H., Khan N, Siraj M. Khan G. A. (2000). ―Demonstration of pepsin activity in circulating immune complexes isolated from diabetic patients‖. International Journal of Diabetes in Developing Countries, 20: 122-128.
Isik1 A, Okan I, Firat D, Yilmaz B, Akcakava A, Sahin M. (2014). A new prognostic strategy for gastric carcinoma: albumin level and metastatic lymph node ratio.
Minerva Chirurgica, 69(3): 147-153.
Isik2 A, Peker K, Firat D, Yilmaz B, Sayer I, Idiz O, Caker C, Demirylmaz I, Yilmaz I.
(2014). Impotance of metastatic lymph node reaction in non-metastatic, lymph node-invaded colon cancer: A clinical trial. Medical Science Monitor, 20: 1369-1375.
Jäger E, Gnjatic S, Nagata Y, Stockert E, Jäger D, Karbach J, Neumann A, Rieckenberg J, Chen Y. T, Ritter G, Hoffman E, Arand M, Old L. J, Knuth A (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proceedings of National Academy of Science: USA, 97:12198-12203.
Jager E, Jager D, Kunth A (2002) Clinical Cancer vaccine trials. Current Opinions in Immunology, 14: 178-182.
Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H.
Wada, Y. Noguchi, E. Stockert, L. J. Old, and Knuth A. (1998). Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:
definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. Journal of Experimental Medicine, 187:265-270.
Janeway C A Jnr., Travers P. Walport M (2001). The immune system in health and disease.
Garland Science Pub. New York. Pp 145-153.
Jaramillo, A., K. Majumder, P. P. Manna, T. P. Fleming, G. Doherty, J. F. Dipersio, and T.
Mohanakumar. (2002).Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer.
International Journal of Cancer, 102: 499-506.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T (2008). Cancer statistics. Clinical Journal of Cancer, 58:71–96.
Jenkins C. R., Shevchuk D.. O, Galambia V., Larn S. H., Garborl J. M., Wang A. P. (2012).
IGF signaling contributes to malignant transformation of haemopoietic progenitor by MLL-AF9 oncoprotein. Experimental Haematology, 4(9): 715-729.
Jerry D. J. (2007). Roles for estrogen and progesterone in breast cancer prevention. Breast Cancer Research, 9(2):102-107.